Literature DB >> 23851165

Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.

Daniel Tamae1, Michael Byrns, Brett Marck, Elahe A Mostaghel, Peter S Nelson, Paul Lange, Daniel Lin, Mary-Ellen Taplin, Steven Balk, William Ellis, Larry True, Robert Vessella, Bruce Montgomery, Ian A Blair, Trevor M Penning.   

Abstract

Prostate cancer is the most frequently diagnosed form of cancer in males in the United States. The disease is androgen driven and the use of orchiectomy or chemical castration, known as androgen deprivation therapy (ADT) has been employed for the treatment of advanced prostate cancer for over 70 years. Agents such as GnRH agonists and non-steroidal androgen receptor antagonists are routinely used in the clinic, but eventually relapse occurs due to the emergence of castration-resistant prostate cancer. With the appreciation that androgen signaling still persists in these patients and the development of new therapies such as abiraterone and enzalutamide that further suppresses androgen synthesis or signaling, there is a renewed need for sensitive and specific methods to quantify androgen precursor and metabolite levels to assess drug efficacy. We describe the development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization selected reaction monitoring mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of serum keto-androgens and their sulfate and glucuronide conjugates using Girard-T oxime derivatives. The method is robust down to 0.2-4pg on column, depending on the androgen metabolite quantified, and can also quantify dehydroepiandrosterone sulfate (DHEA-S) in only 1μL of serum. The clinical utility of this method was demonstrated by analyzing serum androgens from patients enrolled in a clinical trial assessing combinations of pharmacological agents to maximally suppress gonadal and adrenal androgens (Targeted Androgen Pathway Suppression, TAPS clinical trial). The method was validated by correlating the results obtained with a hydroxylamine derivatization procedure coupled with tandem mass spectrometry using selected reaction monitoring that was conducted in an independent laboratory.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5α-androstane-3,17-dione; 5α-dihydrotestosterone; A; ADT; Adione; Androgen metabolome; CD-FBS; CRPC; CV; DHEA; DHEA-G; DHEA-S; DHT; ELISA; Epi-T; GnRH; HSD; LC; LLOQ; Mass spectrometry; ND; NS; PSA; Prostate cancer; QC; RIA; SID-LC/ESI/SRM/MS; T; TAPS; TFA; Targeted Androgen Pathway Suppression clinical trial; UDP glucuronosyltransferase; UGT; androgen deprivation therapy; androsterone; castration resistant prostate cancer; charcoal dextran stripped fetal bovine serum; coefficient of variation; dehydroepiandrosterone; dehydroepiandrosterone glucuronide; dehydroepiandrosterone sulfate; enzyme-linked immunosorbent assay; epitestosterone; gonadotropin releasing hormone; hydroxysteroid dehydrogenase; liquid chromatography; lower limit of quantification; m/z; mass to charge ratio; not detected; not significant; prostate specific antigen; quality control; radioimmunoassay; stable isotope dilution liquid chromatography electrospray ionization selected reaction monitoring mass spectrometry; testosterone; trifluoroacetic acid; Δ(4)-AD; Δ(4)-androstene-3,17-dione

Mesh:

Substances:

Year:  2013        PMID: 23851165      PMCID: PMC3866616          DOI: 10.1016/j.jsbmb.2013.06.014

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  32 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.

Authors:  Christina Wang; Don H Catlin; Laurence M Demers; Borislav Starcevic; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

Review 3.  The backdoor pathway to dihydrotestosterone.

Authors:  Richard J Auchus
Journal:  Trends Endocrinol Metab       Date:  2004-11       Impact factor: 12.015

Review 4.  Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.

Authors:  Fernand Labrie; Leonello Cusan; José Gomez; Van Luu-The; Bernard Candas; Alain Bélanger; Claude Labrie
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-21       Impact factor: 4.292

5.  Sodium ascorbate improves yield of urinary steroids during hydrolysis with Helix pomatia juice.

Authors:  Sofia Christakoudi; David A Cowan; Norman F Taylor
Journal:  Steroids       Date:  2007-11-22       Impact factor: 2.668

6.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

7.  Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques.

Authors:  Valérie Moal; Elisabeth Mathieu; Pascal Reynier; Yves Malthièry; Yves Gallois
Journal:  Clin Chim Acta       Date:  2007-07-19       Impact factor: 3.786

8.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Measuring urinary testosterone levels of the great apes--problems with enzymatic hydrolysis using Helix pomatia juice.

Authors:  Barbara Hauser; Doreen Schulz; Christophe Boesch; Tobias Deschner
Journal:  Gen Comp Endocrinol       Date:  2008-05-27       Impact factor: 2.822

10.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Authors:  Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

View more
  15 in total

Review 1.  Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.

Authors:  Qingqing Wang; Lisa Bottalico; Clementina Mesaros; Ian A Blair
Journal:  Steroids       Date:  2014-08-20       Impact factor: 2.668

Review 2.  Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer.

Authors:  Trevor M Penning
Journal:  Vitam Horm       Date:  2018-02-24       Impact factor: 3.421

3.  Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry.

Authors:  Qingqing Wang; Kannan Rangiah; Clementina Mesaros; Nathaniel W Snyder; Anil Vachani; Haifeng Song; Ian A Blair
Journal:  Steroids       Date:  2015-01-29       Impact factor: 2.668

4.  Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Authors:  Tianzhu Zang; Mary-Ellen Taplin; Daniel Tamae; Wanling Xie; Clementina Mesaros; Zhenwei Zhang; Glenn Bubley; Bruce Montgomery; Steven P Balk; Elahe A Mostaghel; Ian A Blair; Trevor M Penning
Journal:  Endocr Relat Cancer       Date:  2017-06-29       Impact factor: 5.678

5.  Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Tianzhu Zang; Daniel Tamae; Clementina Mesaros; Qingqing Wang; Meng Huang; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2016-08-12       Impact factor: 4.292

6.  What are the main considerations for bioanalysis of estrogens and androgens in plasma and serum samples from postmenopausal women?

Authors:  Clementina Mesaros; Qingqing Wang; Ian A Blair
Journal:  Bioanalysis       Date:  2014       Impact factor: 2.681

Review 7.  The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

Authors:  Daniel Tamae; Elahe Mostaghel; Bruce Montgomery; Peter S Nelson; Steven P Balk; Philip W Kantoff; Mary-Ellen Taplin; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2014-12-13       Impact factor: 5.192

8.  External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.

Authors:  Eunpi Cho; Elahe A Mostaghel; Kenneth J Russell; Jay J Liao; Mark A Konodi; Brenda F Kurland; Brett T Marck; Alvin M Matsumoto; Bruce L Dalkin; R Bruce Montgomery
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-12       Impact factor: 7.038

Review 9.  Androgen biosynthesis in castration-resistant prostate cancer.

Authors:  Trevor M Penning
Journal:  Endocr Relat Cancer       Date:  2014-05-14       Impact factor: 5.678

Review 10.  Ultra-high sensitivity analysis of estrogens for special populations in serum and plasma by liquid chromatography-mass spectrometry: Assay considerations and suggested practices.

Authors:  Qingqing Wang; Clementina Mesaros; Ian A Blair
Journal:  J Steroid Biochem Mol Biol       Date:  2016-01-06       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.